Skip to main content
Signal8

Journey Medical Corp (DERM)

Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.

Sector: Pharmaceutical Preparations

Industry: Drug Manufacturers - Specialty & Generic

Journey Medical Corporation logo

Journey Medical Corporation

NASDAQ:DERMHealthcare
-1.00%$4.97
AH Close$4.96-0.12%vs close
Mkt Cap$140.28M
Float12.04M
O/S28.22M
Inst Own36.2%
SI25.4%
Dilution
Journey Medical Corporation logoNASDAQ:DERM$4.97-1.00%
Historical Data
DateOpenHighLowCloseVolume
Key Metrics
Market Cap$140.28M
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership36.19%

based on 28.22M shares outstanding

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ExchangeNASDAQ
CountryUSUS
IPO DateNov 12, 2021
Shares Outstanding28.22M
Float12.04M
Company Overview

Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.

Leadership

Claude Maraoui

Founder, President, Chief Executive Officer & Director

Justin Smith

Director

Lindsay A. Rosenwald, M.D.

Executive Chairman of the Board of Directors

Michael Pearce

Director

Employees

58

Country

US

Sector

Healthcare

Website

journeymedicalcorp.com

Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
No price targets available
Ratings Distribution
BUY
3
HOLD
0
SELL
0
TOTAL3
Insider Trades
InsiderTypeShares
Smith Justin Adam profile photoSmith Justin AdamGrant/Award50.0K
Herskowitz Neil profile photoHerskowitz NeilGrant/Award50.0K
Toledano Miranda Jayne profile photoToledano Miranda JayneGrant/Award50.0K
Smith Justin Adam profile photoSmith Justin AdamGrant/Award10.0K
Herskowitz Neil profile photoHerskowitz NeilGrant/Award10.0K
ROSENWALD LINDSAY A MD profile photoROSENWALD LINDSAY A MDGrant/Award10.0K
Shareholders
36.2%
Institutional
(69)
14.7%
Insiderⓘ
(8)
0.0%
5%+ Owners
(0)
49.1%
Unattributed (incl. retail)ⓘ
Institutional36.2%
Insider14.7%
Unattributed (incl. retail)49.1%
Sources: 13F, Form 4, 13D/13GO/S: 28.2M · checked 26 Oct 2026 · market-data provider
Insiders & Institutional Holders
52-Week Range
$4.31$9.55
$4.97(13th percentile)
Volume
Average Daily Volume186.44K
118.58K today vs 186.44K avg(-36%)

30d Avg

186.44K

60d Avg

183.07K

90d Avg

195.81K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...